advertisement

Cancer

11 June 2010

Cancer drug tied to kidney damage

The widely used cancer drug bevacizumab (Avastin) is associated with a more than fourfold increased risk of severe urinary protein loss, a new review finds.

The widely used cancer drug bevacizumab (Avastin) is associated with a more than fourfold increased risk of severe urinary protein loss, a new review finds.

In the review, 2.2% of the patients taking Avastin experienced severe proteinura, with patients who were taking the highest doses of the drug facing an even higher risk. Also, the type of cancer played a role in the risk of kidney trouble, with kidney cancer patients seeing the greatest risk (10.2%).

Avastin recently approved

Kidney cancer is the eighth most commonly diagnosed cancer in the United States. The cancer society estimates that there will be about 57 760 new cases of kidney cancer in the United States this year, and about 12,980 people will die from the disease. - (HealthDay News, June 2010)

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules